Dr. Reddy's Semaglutide Batches Out of Specification

Key Event

Certain batches of the product semaglutide were found to be out of specification. The issue is associated with the active pharmaceutical ingredient (API) used in the product.

Company Actions

The company is investigating the root cause of the issue and is taking appropriate measures to ensure product quality.

Operational Impact

Until the issue is resolved, commercial supplies of the product will be delayed for a certain period of time.

Safety and Regulatory Impact

There is no impact on patient safety. There is no impact on the product's existing global regulatory filings.

Management Commentary

The company states it remains committed to ensuring reliable global supplies of this important metabolic therapy.

Investor Communication

The management will host a conference call to discuss the topic on Thursday, July 9, 2026, from 16:30 to 17:00 IST (07:00 to 07:30 ET).

Disclosing Officer

The disclosure was signed by K Randhir Singh, Company Secretary, Compliance Officer & Head-CSR, on July 9, 2026.